stockportfolio.pro
Moderna, Inc. P/E Ratio 2016–2025
Moderna, Inc. (MRNA) annual price-to-earnings ratio by fiscal year, computed from SEC filings. Compound growth -0.1%/yr over 9 years.
| Fiscal year | P/E Ratio | Change (YoY) |
|---|---|---|
| FY 2025 | — | — |
| FY 2024 | — | — |
| FY 2023 | — | — |
| FY 2022 | 8.93 | -0.6% |
| FY 2021 | 8.98 | — |
| FY 2020 | — | — |
| FY 2019 | — | — |
| FY 2018 | — | — |
| FY 2017 | — | — |
| FY 2016 | — | — |
Source: Moderna, Inc. SEC filings — fiscal-year-end price ÷ diluted EPS. Refreshed nightly.
See the full picture for Moderna, Inc.
Complete income statement, balance sheet and cash flow with trend on every row, 48 quarters, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open the interactive view — freeModerna, Inc. — frequently asked questions
What is Moderna, Inc.'s price-to-earnings ratio?
Moderna, Inc. (MRNA) reported price-to-earnings ratio of 8.93 for fiscal year 2022, per its SEC filings.
How has Moderna, Inc.'s price-to-earnings ratio changed over time?
Between fiscal 2016 and 2025, MRNA's price-to-earnings ratio declined at roughly 0.1% per year (compound annual rate), from 8.98 to 8.93.
Where does this data come from?
Figures are computed from Moderna, Inc.'s official SEC filings (fiscal-year-end price ÷ diluted EPS), refreshed nightly. Not investment advice.